{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:54:10Z","timestamp":1791154450617,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T00:00:00Z","timestamp":1290470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cancers that grow in bone, such as myeloma and breast cancer metastases, cause devastating osteolytic bone destruction. These cancers hijack bone remodeling by stimulating osteoclastic bone resorption and suppressing bone formation. Currently, treatment is targeted primarily at blocking bone resorption, but this approach has achieved only limited success. Stimulating osteoblastic bone formation to promote repair is a novel alternative approach. We show that a soluble activin receptor type IIA fusion protein (ActRIIA.muFc) stimulates osteoblastogenesis (p\u2009&amp;lt;\u2009.01), promotes bone formation (p\u2009&amp;lt;\u2009.01) and increases bone mass in vivo (p\u2009&amp;lt;\u2009.001). We show that the development of osteolytic bone lesions in mice bearing murine myeloma cells is caused by both increased resorption (p\u2009&amp;lt;\u2009.05) and suppression of bone formation (p\u2009&amp;lt;\u2009.01). ActRIIA.muFc treatment stimulates osteoblastogenesis (p\u2009&amp;lt;\u2009.01), prevents myeloma-induced suppression of bone formation (p\u2009&amp;lt;\u2009.05), blocks the development of osteolytic bone lesions (p\u2009&amp;lt;\u2009.05), and increases survival (p\u2009&amp;lt;\u2009.05). We also show, in a murine model of breast cancer bone metastasis, that ActRIIA.muFc again prevents bone destruction (p\u2009&amp;lt;\u2009.001) and inhibits bone metastases (p\u2009&amp;lt;\u2009.05). These findings show that stimulating osteoblastic bone formation with ActRIIA.muFc blocks the formation of osteolytic bone lesions and bone metastases in models of myeloma and breast cancer and paves the way for new approaches to treating this debilitating aspect of cancer. \u00a9 2010 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.142","type":"journal-article","created":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T20:53:12Z","timestamp":1275943992000},"page":"2633-2646","source":"Crossref","is-referenced-by-count":133,"title":["Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo"],"prefix":"10.1093","volume":"25","author":[{"given":"Andrew D","family":"Chantry","sequence":"first","affiliation":[{"name":"Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debby","family":"Heath","sequence":"additional","affiliation":[{"name":"Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron W","family":"Mulivor","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Pearsall","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Baud'huin","sequence":"additional","affiliation":[{"name":"Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les","family":"Coulton","sequence":"additional","affiliation":[{"name":"Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Evans","sequence":"additional","affiliation":[{"name":"Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Abdul","sequence":"additional","affiliation":[{"name":"Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D","family":"Werner","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L","family":"Bouxsein","sequence":"additional","affiliation":[{"name":"Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L","family":"Key","sequence":"additional","affiliation":[{"name":"Department of Cell and Developmental Biology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasbir","family":"Seehra","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R","family":"Arnett","sequence":"additional","affiliation":[{"name":"Department of Cell and Developmental Biology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[{"name":"Department Hematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Croucher","sequence":"additional","affiliation":[{"name":"Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,11,23]]},"reference":[{"key":"2024020320085929200_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer."},{"key":"2024020320085929200_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev."},{"key":"2024020320085929200_bib3","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille","year":"1989","journal-title":"J Clin Oncol."},{"key":"2024020320085929200_bib4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N Engl J Med."},{"key":"2024020320085929200_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest."},{"key":"2024020320085929200_bib6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol."},{"key":"2024020320085929200_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0609.2000.90074.x","article-title":"Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma","volume":"64","author":"Abildgaard","year":"2000","journal-title":"Eur J Haematol."},{"key":"2024020320085929200_bib8","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med."},{"key":"2024020320085929200_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol."},{"key":"2024020320085929200_bib10","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1002\/1097-0142(20000615)88:12+<3022::AID-CNCR19>3.0.CO;2-R","article-title":"Bisphosphonates in multiple myeloma","author":"Kanis","year":"2000","journal-title":"Cancer 88(12 Suppl)."},{"key":"2024020320085929200_bib11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer."},{"key":"2024020320085929200_bib12","first-page":"D003188","article-title":"Bisphosphonates in multiple myeloma","author":"Djulbegovic","year":"2002","journal-title":"Cochrane Database Syst Rev (3):C."},{"key":"2024020320085929200_bib13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer."},{"key":"2024020320085929200_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/321779a0","article-title":"Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin","volume":"321","author":"Ling","year":"1986","journal-title":"Nature."},{"key":"2024020320085929200_bib15","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/321776a0","article-title":"Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid","volume":"321","author":"Vale","year":"1986","journal-title":"Nature."},{"key":"2024020320085929200_bib16","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1073\/pnas.74.12.5721","article-title":"Evidence for ovarian \u201cinhibin\u201d: suppression of the secondary rise in serum follicle stimulating hormone levels in proestrous rats by injection of porcine follicular fluid","volume":"74","author":"Schwartz","year":"1977","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020320085929200_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev.ph.57.030195.001251","article-title":"Inhibin, activin and the female reproductive axis","volume":"57","author":"Woodruff","year":"1995","journal-title":"Annu Rev Physiol."},{"key":"2024020320085929200_bib18","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1242\/dev.120.12.3621","article-title":"Expression of activin subunits, activin receptors and follistatin in postimplantation mouse embryos suggests specific developmental functions for different activins","volume":"120","author":"Feijen","year":"1994","journal-title":"Development."},{"key":"2024020320085929200_bib19","first-page":"1521","article-title":"The tissue distribution of activin beta A- and beta B-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development","volume":"78","author":"Tuuri","year":"1994","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020320085929200_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/MCB.25.1.60-65.2005","article-title":"MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration","volume":"25","author":"Zhang","year":"2005","journal-title":"Mol Cell Biol."},{"key":"2024020320085929200_bib21","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1093\/emboj\/18.19.5205","article-title":"Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair","volume":"18","author":"Munz","year":"1999","journal-title":"EMBO J."},{"key":"2024020320085929200_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/153537020222700201","article-title":"Regulation of cell proliferation, apoptosis, and carcinogenesis by activin","volume":"227","author":"Chen","year":"2002","journal-title":"Exp Biol Med (Maywood)."},{"key":"2024020320085929200_bib23","doi-asserted-by":"crossref","first-page":"14233","DOI":"10.1016\/S0021-9258(19)49702-0","article-title":"Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation","volume":"267","author":"Ogawa","year":"1992","journal-title":"J Biol Chem."},{"key":"2024020320085929200_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.0.CO;2-T","article-title":"Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells","volume":"75","author":"Ikenoue","year":"1999","journal-title":"J Cell Biochem."},{"key":"2024020320085929200_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/endo.143.1.8580","article-title":"Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures","volume":"143","author":"Gaddy-Kurten","year":"2002","journal-title":"Endocrinology."},{"key":"2024020320085929200_bib26","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1096\/fj.07-8080com","article-title":"The activin A-follistatin system: potent regulator of human extracellular matrix mineralization","volume":"21","author":"Eijken","year":"2007","journal-title":"Faseb J."},{"key":"2024020320085929200_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/bbrc.2000.2075","article-title":"Activin A is an essential cofactor for osteoclast induction","volume":"268","author":"Fuller","year":"2000","journal-title":"Biochem Biophys Res Commun."},{"key":"2024020320085929200_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/8756-3282(94)90301-8","article-title":"Effect of local injection of activin A on bone formation in newborn rats","volume":"15","author":"Oue","year":"1994","journal-title":"Bone."},{"key":"2024020320085929200_bib29","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1210\/en.2006-0848","article-title":"Inhibin A is an endocrine stimulator of bone mass and strength","volume":"148","author":"Perrien","year":"2007","journal-title":"Endocrinology."},{"key":"2024020320085929200_bib30","first-page":"261","article-title":"Role of transforming growth factor-beta in bone remodeling","author":"Bonewald","year":"1990","journal-title":"Clin Orthop Relat Res (250)."},{"key":"2024020320085929200_bib31","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1073\/pnas.0711263105","article-title":"A soluble activin type IIA receptor induces bone formation and improves skeletal integrity","volume":"105","author":"Pearsall","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020320085929200_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","article-title":"Activin A circulating levels in patients with bone metastasis from breast or prostate cancer","volume":"23","author":"Leto","year":"2006","journal-title":"Clin Exp Metastasis."},{"key":"2024020320085929200_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jcp.10321","article-title":"Hypoxia is a major stimulator of osteoclast formation and bone resorption","volume":"196","author":"Arnett","year":"2003","journal-title":"J Cell Physiol."},{"key":"2024020320085929200_bib34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4049\/jimmunol.122.2.609","article-title":"Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice","volume":"122","author":"Radl","year":"1979","journal-title":"J Immunol."},{"key":"2024020320085929200_bib35","first-page":"191","article-title":"The 5T2MM murine model of multiple myeloma: maintenance and analysis","volume":"113","author":"Vanderkerken","year":"2005","journal-title":"Methods Mol Med."},{"key":"2024020320085929200_bib36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1359\/jbmr.070507","article-title":"Age-related changes in trabecular architecture differ in female and male C57BL\/6J mice","volume":"22","author":"Glatt","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024020320085929200_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res."},{"key":"2024020320085929200_bib38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1600-065X.2003.00035.x","article-title":"Multiple myeloma biology: lessons from the 5TMM models","volume":"194","author":"Vanderkerken","year":"2003","journal-title":"Immunol Rev."},{"key":"2024020320085929200_bib39","author":"Ottewell"},{"key":"2024020320085929200_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020320085929200_bib41","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bone.2010.01.370","article-title":"A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys","volume":"46","author":"Lotinun","year":"2010","journal-title":"Bone."},{"key":"2024020320085929200_bib42","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/1078-0432.CCR-07-1221","article-title":"Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice","volume":"14","author":"Ogino","year":"2008","journal-title":"Clin Cancer Res."},{"key":"2024020320085929200_bib43","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreases osteolysis, tumour burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"2024020320085929200_bib44","first-page":"287","article-title":"Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res."},{"key":"2024020320085929200_bib45","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res."},{"key":"2024020320085929200_bib46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"2024020320085929200_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2007-11-124164","article-title":"Role of decorin in the antimyeloma effects of osteoblasts","volume":"112","author":"Li","year":"2008","journal-title":"Blood."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.142","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/25\/12\/2633\/56578093\/jbmr142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/25\/12\/2633\/56578093\/jbmr142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:45:35Z","timestamp":1710341135000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/25\/12\/2633-2646\/7600209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,23]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,11,23]]},"published-print":{"date-parts":[[2010,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.142","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,12,1]]},"published":{"date-parts":[[2010,11,23]]}}}